Literature DB >> 21656753

Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations.

Kathryn C Amirikia1, Paul Mills, Jason Bush, Lisa A Newman.   

Abstract

BACKGROUND: Differences in the breast cancer burden of African-American women compared with white American women are well documented. Recent controversies have emerged regarding age-appropriate mammographic screening guidelines, and these surveillance recommendations may influence future breast cancer disparities. The objective of the current study was to evaluate age-specific breast cancer stage distributions and incidence rates of triple-negative breast cancer (TNBC) in a population-based tumor registry.
METHODS: The authors analyzed breast cancers from the California Cancer Registry (CCR) that were diagnosed between 1988 and 2006. The results were stratified by age and race/ethnicity, with white Americans identified as non-Hispanic whites (NHWs) and African Americans identified as non-Hispanic blacks (NHBs). Breast cancer stage distributions and TNBC incidence rates also were analyzed.
RESULTS: In total, 375,761 invasive breast cancers were evaluated (including 276,938 in NHWs and 21,681 in NHBs). NHBs and Hispanics tended to be younger than NHWs (median ages 57 years, 54 years, and 64 years, respectively). Lifetime incidence rates were higher for NHWs compared with NHBs and Hispanics; however, for women aged <44 years, incidence was highest among NHBs. NHBs also had higher incidence rates of stage III and IV disease and a higher incidence of TNBC in all age categories.
CONCLUSIONS: Population-based data demonstrated that African-American women had a more advanced stage distribution for breast cancer compared with white American women and higher incidence rates for TNBC. These patterns were observed for women ages 40 to 49 years and for older women, and they suggest that mammographic screening for the early detection of breast cancer will be particularly relevant for younger African-American women.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 21656753      PMCID: PMC3461243          DOI: 10.1002/cncr.25862

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Authors:  Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

Authors:  William F Anderson; Nilanjan Chatterjee; William B Ershler; Otis W Brawley
Journal:  Breast Cancer Res Treat       Date:  2002-11       Impact factor: 4.872

3.  Effect of screening and adjuvant therapy on mortality from breast cancer.

Authors:  Donald A Berry; Kathleen A Cronin; Sylvia K Plevritis; Dennis G Fryback; Lauren Clarke; Marvin Zelen; Jeanne S Mandelblatt; Andrei Y Yakovlev; J Dik F Habbema; Eric J Feuer
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

4.  Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women?

Authors:  Alero Fregene; Lisa A Newman
Journal:  Cancer       Date:  2005-04-15       Impact factor: 6.860

5.  Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.

Authors:  Katrina R Bauer; Monica Brown; Rosemary D Cress; Carol A Parise; Vincent Caggiano
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

6.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  Reproductive factors and risk of breast carcinoma in a study of white and African-American women.

Authors:  Giske Ursin; Leslie Bernstein; Yaping Wang; Sarah J Lord; Dennis Deapen; Jonathan M Liff; Sandra A Norman; Linda K Weiss; Janet R Daling; Polly A Marchbanks; Kathleen E Malone; Suzanne G Folger; Jill A McDonald; Ronald T Burkman; Michael S Simon; Brian L Strom; Robert Spirtas
Journal:  Cancer       Date:  2004-07-15       Impact factor: 6.860

Review 9.  Screening for breast cancer: an update for the U.S. Preventive Services Task Force.

Authors:  Heidi D Nelson; Kari Tyne; Arpana Naik; Christina Bougatsos; Benjamin K Chan; Linda Humphrey
Journal:  Ann Intern Med       Date:  2009-11-17       Impact factor: 25.391

10.  Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database.

Authors:  Gloria J Morris; Sashi Naidu; Allan K Topham; Fran Guiles; Yihuan Xu; Peter McCue; Gordon F Schwartz; Pauline K Park; Anne L Rosenberg; Kristin Brill; Edith P Mitchell
Journal:  Cancer       Date:  2007-08-15       Impact factor: 6.860

View more
  82 in total

Review 1.  Clinical implications of molecular heterogeneity in triple negative breast cancer.

Authors:  Brian D Lehmann; Jennifer A Pietenpol
Journal:  Breast       Date:  2015-08-05       Impact factor: 4.380

2.  Increasing disparities in breast cancer mortality from 1979 to 2010 for US black women aged 20 to 49 years.

Authors:  Anne Marie McCarthy; Jianing Yang; Katrina Armstrong
Journal:  Am J Public Health       Date:  2015-04-23       Impact factor: 9.308

Review 3.  Breast cancer metastasis through the lympho-vascular system.

Authors:  S David Nathanson; David Krag; Henry M Kuerer; Lisa A Newman; Markus Brown; Dontscho Kerjaschki; Ethel R Pereira; Timothy P Padera
Journal:  Clin Exp Metastasis       Date:  2018-05-23       Impact factor: 5.150

Review 4.  Racial disparity in breast cancer: can it be mattered for prognosis and therapy.

Authors:  Vijayalaxmi Gupta; Inamul Haque; Jinia Chakraborty; Stephanie Graff; Snigdha Banerjee; Sushanta K Banerjee
Journal:  J Cell Commun Signal       Date:  2017-11-29       Impact factor: 5.782

Review 5.  Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.

Authors:  Abenaa M Brewster; Mariana Chavez-MacGregor; Powel Brown
Journal:  Lancet Oncol       Date:  2014-11-24       Impact factor: 41.316

Review 6.  Population and target considerations for triple-negative breast cancer clinical trials.

Authors:  Terry Hyslop; Yvonne Michael; Tiffany Avery; Hallgeir Rui
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

7.  US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.

Authors:  Nadia Howlader; Sean F Altekruse; Christopher I Li; Vivien W Chen; Christina A Clarke; Lynn A G Ries; Kathleen A Cronin
Journal:  J Natl Cancer Inst       Date:  2014-04-28       Impact factor: 13.506

8.  Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes.

Authors:  Jie Shen; Li Yan; Song Liu; Christine B Ambrosone; Hua Zhao
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

9.  Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.

Authors:  Delisha A Stewart; Jason H Winnike; Susan L McRitchie; Robert F Clark; Wimal W Pathmasiri; Susan J Sumner
Journal:  J Proteome Res       Date:  2016-08-03       Impact factor: 4.466

10.  Nuclear localization of Kaiso promotes the poorly differentiated phenotype and EMT in infiltrating ductal carcinomas.

Authors:  Jacqueline Jones; Honghe Wang; Balasubramanyam Karanam; Shaniece Theodore; Windy Dean-Colomb; Danny R Welch; William Grizzle; Clayton Yates
Journal:  Clin Exp Metastasis       Date:  2014-02-26       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.